Our flagship project is a patented enterovirus based preventive Type 1 Diabetes (T1D) vaccine, similar to the widely used enterovirus vaccine against polio. Our other projects include new treatments and diagnostics for Celiac Disease, all covered by patents.
Type 1 Diabetes is one of the most common chronic, life-long diseases globally, and it is most often diagnosed in children, adolescents and young adults.
Vactech is developing a vaccine for the prevention of Type 1 Diabetes.
In addition to Type 1 Diabetes Vactech is developing applications in the fields of Diagnostics, Asthma & Allergy, Celiac Disease and Virus Like Particles.